Literature DB >> 24815327

Risk of and factors associated with readmission after a sentinel attack of acute pancreatitis.

Kishore Vipperla1, Georgios I Papachristou1, Jeffrey Easler1, Venkata Muddana1, Adam Slivka1, David C Whitcomb1, Dhiraj Yadav2.   

Abstract

BACKGROUND & AIMS: Few data are available on how many patients are readmitted to the hospital after attacks of acute pancreatitis. We aimed to determine the risk and factors that determine early (within 30 days) and late (after 30 days) readmission of patients with acute pancreatitis.
METHODS: In a retrospective study, we collected and analyzed data on 127 surviving patients (median age, 53 y; 52% male; 83% white) hospitalized at the University of Pittsburgh Medical Center for a sentinel attack of acute pancreatitis, enrolled in the Severe Acute Pancreatitis Study from June 2003 through April 2010, and who had follow-up data. Information was collected on demographics, clinical profile, risk score at discharge (based on a recently developed scoring system), and details of readmissions during the follow-up period (median, 36 mo).
RESULTS: Of the 127 patients, 52% were transfers from another care center and 32% required admission to the intensive care unit. Etiologies for pancreatitis were biliary (47%), idiopathic (13%), alcohol associated (12%), and others (28%). Pancreatic necrosis (28%), persistent organ failure (27%), and peripancreatic fluid collections (19%) were common. The median length of stay was 9 days. A total of 108 readmissions occurred for 43 patients (34%). Early readmissions (n = 21) occurred more frequently for patients with smoldering (ongoing) symptoms or local complications than for those without. Late readmissions (n = 22) occurred more frequently for patients with recurrent pancreatitis than for those without. Male sex, alcohol-associated disease, and severe disease increased the risks of readmission and recurrence. The risk for readmission was lower among nontransferred patients (23%) and patients without necrosis or organ failure (16%). Risk for readmission increased with the number of points on the weighted scoring system.
CONCLUSIONS: Approximately one-third of patients hospitalized for acute pancreatitis are readmitted, usually as a result of smoldering symptoms, local complications, or recurrent attacks. Studies are needed to determine whether individualized discharge planning, with consideration of the etiology of acute pancreatitis, can reduce the risk for readmission.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; Outcome; Pancreas; Prognostic Factor

Mesh:

Year:  2014        PMID: 24815327     DOI: 10.1016/j.cgh.2014.04.035

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  28 in total

1.  The Changing Epidemiology of Acute Pancreatitis Hospitalizations: A Decade of Trends and the Impact of Chronic Pancreatitis.

Authors:  Somashekar G Krishna; Amrit K Kamboj; Phil A Hart; Alice Hinton; Darwin L Conwell
Journal:  Pancreas       Date:  2017-04       Impact factor: 3.327

2.  Cholecystectomy During Index Admission for Acute Biliary Pancreatitis Lowers 30-Day Readmission Rates.

Authors:  Somashekar G Krishna; Andrew J Kruger; Nishi Patel; Alice Hinton; Dhiraj Yadav; Darwin L Conwell
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

3.  Influence of Ambulatory Triglyceride Levels on Risk of Recurrence in Patients with Hypertriglyceridemic Pancreatitis.

Authors:  Bechien U Wu; Michael Batech; Elizabeth Y Dong; Lewei Duan; Dhiraj Yadav; Wansu Chen
Journal:  Dig Dis Sci       Date:  2018-08-09       Impact factor: 3.199

4.  Opiate Prescriptions at Discharge Are Not Associated with Early Readmissions in Acute Pancreatitis.

Authors:  Allison L Yang; David X Jin; Meghan Rudder; Shadeah Suleiman; Peter A Banks; Julia McNabb-Baltar
Journal:  Dig Dis Sci       Date:  2019-08-22       Impact factor: 3.199

5.  Rate of recurrence in Indian patients presenting with acute pancreatitis and identification of chronicity on follow up: Possible risk factors for progression.

Authors:  Rishikesh Kalaria; Philip Abraham; Devendra C Desai; Anand Joshi; Tarun Gupta
Journal:  Indian J Gastroenterol       Date:  2018-03-07

6.  Risk Factors for Adverse Outcomes in Patients Hospitalized With Lower Gastrointestinal Bleeding.

Authors:  Neil Sengupta; Elliot B Tapper; Vilas R Patwardhan; Gyanprakash A Ketwaroo; Adarsh M Thaker; Daniel A Leffler; Joseph D Feuerstein
Journal:  Mayo Clin Proc       Date:  2015-07-02       Impact factor: 7.616

7.  Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development and Trials in Recurrent Acute Pancreatitis at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Authors:  Mark E Lowe; Marc T Goodman; Gregory A Coté; Marshall J Glesby; Mark Haupt; Nicholas J Schork; Vikesh K Singh; Dana K Andersen; Stephen J Pandol; Aliye Uc; David C Whitcomb
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

8.  The Pancreatitis Activity Scoring System predicts clinical outcomes in acute pancreatitis: findings from a prospective cohort study.

Authors:  James Buxbaum; Michael Quezada; Bradford Chong; Nikhil Gupta; Chung Yao Yu; Christianne Lane; Ben Da; Kenneth Leung; Ira Shulman; Stephen Pandol; Bechien Wu
Journal:  Am J Gastroenterol       Date:  2018-03-15       Impact factor: 10.864

9.  High Rates of Readmission in Necrotizing Pancreatitis: Natural History or Opportunity for Improvement?

Authors:  Thomas K Maatman; Sarakshi Mahajan; Alexandra M Roch; Kyle A Lewellen; Mark A Heimberger; Cameron L Colgate; Eugene P Ceppa; Michael G House; Attila Nakeeb; C Max Schmidt; Nicholas J Zyromski
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

10.  Risk of New-Onset Diabetes Is Determined by Severity of Acute Pancreatitis.

Authors:  Kishore Vipperla; Georgios I Papachristou; Adam Slivka; David C Whitcomb; Dhiraj Yadav
Journal:  Pancreas       Date:  2016-01       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.